Benzinga | Sep 18, 2020 08:17AM EDT

Citigroup Downgrades Mirati Therapeutics to Neutral, Raises Price Target to $183

Citigroup analyst Yigal Nochomovitz downgrades Mirati Therapeutics (NASDAQ:MRTX) from Buy to Neutral and raises the price target from $127 to $183.Citigroup analyst Yigal Nochomovitz downgrades Mirati Therapeutics (NASDAQ:MRTX) from Buy to Neutral and raises the price target from $127 to $183.